Citations

Clear

22 citation(s) found for "Kumar, Naveen".

Population‐Based Epidemiology of Autoimmune Seizures and Epilepsies
Thakolwiboon, Smathorn , Wood, Kathryne N., Paramasivan, Naveen, Smith, Kelsey M., Dasari, Surendra, Devine, Michelle F., McKeon, Andrew , Ζεκερίδου, Αναστασία , Flanagan, Eoin P., Pittock, Sean J., Dubey, Divyanshu , Stabile, Andrea , McKeon, Andrew , Zekeridou, Anastasia , Dubey, Divyanshu , Thakolwiboon, Smathorn , Paramasivan, Naveen Kumar , Britton, Jeffrey W. , Smith, Kelsey M. , DASARI, SURENDRA, Flanagan, Eoin P. , Pittock, Sean J.

Mayo Clinic

Annals of Neurology | March 25, 2026 | Volume: 100 | Issue: 1 | Pages: 74-83

10.1002/ana.78204 | PMID 41876839 Get It

Objective To estimate the prevalence, incidence, and disease burden of autoimmune seizures and epilepsies in Olmsted County. Methods We conducted a retrospective, population‐based study using the Rochester Epidemiology Project (1996–2019). Age‐ and sex‐standardized rates (2019 United States standard population) per 100,000 were calculated with 95% confidence intervals (95% CIs). Temporal trends in incidence were assessed over 3 consecutive 8‐year intervals (1996–2003, 2004–2011, and 2012–2019) using Poisson regression to estimate rate ratios per period and trend. Disability‐adjusted life years (DALYs), years of life lost (YLL), and years lived with disability (YLD) and 95% uncertainty intervals (95% UIs) were estimated for 2019. Results Twenty‐three patients were identified between 1996 and 2019. In 2019, the standardized prevalence of all autoimmune seizures and epilepsies was 9.81 (95% CI, 5.59–15.21) per 100,000, including autoimmune‐associated epilepsy (AAE) 7.27 (3.74–11.95) and acute symptomatic seizures secondary to autoimmune encephalitis (ASSAE) 2.55 (0.69–5.60). From 1996 to 2019, the standardized incidence was 0.50 (0.29–0.77) per 100,000 person‐years overall, with AAE 0.36 (0.19–0.59) and ASSAE 0.15 (0.05–0.30). By period, the standardized incidence of all autoimmune seizures and epilepsies suggested a rising trend from 0.28 (95% CI, 0.06–0.68) in 1996 to 2003 to 0.60 (95% CI, 0.24–1.12) in 2004–2011, then plateaued at 0.53 (95% CI, 0.21–1.00) in 2012 to 2019 (rate ratio per 8‐year interval 1.30, 95% CI, 0.71–2.38), largely driven by the seropositive subgroup. The standardized DALY rate was 26.27 (95% Uncertainly intervals [UI], 5.30–67.09) per 100,000 (YLL 20.07 [0.00–60.21] and YLD 6.20 [5.06–7.39]). Interpretation Although autoimmune seizures and epilepsies remain rare, they result in a disproportionately high disease burden. ANN NEUROL 2026;100:74–83
The aged microenvironment impairs BCL6 and CD40L induction in CD4+ T follicular helper cell differentiation 2437
Fisher, Jacob S. , Barrientos, Irene Adan, Kumar, Naveen , Barrientos, Irene Adán, Lancaster, Jessica N.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.356 Get It

Abstract Description Weakened germinal center responses by the aged immune system result in diminished immunity against pathogens and reduced efficacy of vaccines. Prolonged contacts between activated B cells and CD4+ T cells are crucial to germinal center formation and Tfh differentiation, but it is unclear how aging impacts the quality of this interaction. Peptide immunization confirmed that aged mice have decreased expansion of antigen-specific GC B cells and reduced antibody titers. Aging was associated with accumulated Tfh cells with reduced BCL6 and increased CD39. When activated in vitro by aged antigen-presenting cells, young CD4+ naïve T cells generated reduced numbers of activated cells with upregulated CD40L. To determine the contribution of cell-extrinsic influences on antigen-specific Tfh induction, young, antigen-specific B and CD4+ T cells were transferred into aged hosts prior to immunization. Transferred cells had reduced expansion and differentiation into germinal center B cell and Tfh and reduced antigen-specific antibody titers when compared to young hosts. Young CD4+ T cells transferred into aged hosts differentiated into Tfh cells with reduced PD-1 and BCL6, and increased CD39. Recent studies have focused on immune profiling of CD4 T cells in young and aged mice following immunization. These results highlight the role of the lymphoid microenvironment in modulating CD4+ T cell differentiation, which contributes to impaired initiation and maintenance of germinal centers. Funding Sources Research was supported by NIH/NIA R01 AG080037 and the Mayo Clinic Robert and Arlene Kogod Center on Aging Innovation Award UL1R002377 to J.L. Topic Categories Vaccines and Immunotherapy (VAC)
Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies
Gilligan, Michael , Mills, John R. , Vargas, Paulina, Lesnick, Connie , Basal, Eati, Dasari, Surendra , Fryer, James P., Hinson, Shannon R., LaPorta, Joseph , Espinal, Amy, Fitzgerald, Dennis, Morenkova, Anna , Shah, Anna, Corey, Reghann LaFrance, Lennon, Vanda A. , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Lesnick, Connie E, LaFrance Corey, Reghann, Zekeridou, Anastasia , Pittock, S J , Dubey, Divyanshu , McKeon, Andrew , Vargas, Paulina, Paramasivan, Naveen Kumar , García, Carolina , Pergami, Paola , Knight, Andrew, Corey, Reghann LaFrance, Pittock, Sean J. , Dubey, Divyanshu , McKeon, Andrew

Mayo Clinic

Annals of Clinical and Translational Neurology | November 6, 2025 | Volume: 13 | Issue: 3 | Pages: 547-561

10.1002/acn3.70238 | PMID 41195642 Get It

ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled; October 2022–September 2023. Top‐ranking candidate antigens were validated in silico, by dual‐staining confocal microscopy, and ≥ 1 protein‐specific assay. Clinical data were reviewed. Results Among 21 patients, 11 autoantibodies were characterized (serum, 19; CSF, all 9 available). Autoantigens were CACNA1I, 1; CAMK2B, 2; CLIP2, 1; FMN2, 2; MAP1A, 2; MAP2, 5; NECAB1, 1; SNAP91, 3; SRCIN1, 1; SYNJ1, 1; SYT3, 2. Analytical validation was by confocal TIIFA (all), western blot (10/10 available), and cell‐based assay (5/5 performed). Clinical accompaniments were: encephalitis, 6; brainstem encephalitis, 2; encephalomyelitis, 2; cerebellar ataxia, 2; longitudinally extensive transverse myelitis (LETM), 2; sensory neuronopathy, 1; peripheral neuropathy, 4, and movement disorders, 2. Inflammatory MRI abnormalities were identified in 5/16 patients (31%) with CNS disorders: T2 signal change (2), LETM (2), leptomeningeal enhancement (1). Seven of 8 (88%) had inflammatory CSF (pleocytosis, 5 [median 25.5 cells, range 7–294]; elevated IgG index/synthesis rate, 4; CSF‐exclusive oligoclonal bands, 4). Six had paraneoplastic causation (lung cancer, 2; other, 4); 3 were postinfectious (1 each of COVID‐19, HSV‐1, and post‐Group A streptococcal infection). Of 9 immunotherapy‐treated patients, 5 improved. Interpretation UNAs are partly accounted for by a repertoire of diverse mostly intracellular synaptic antigens. Their characterization is expedited by protein arrays and PhIPSeq. Further individual studies are needed to assess them as disease biomarkers.
Anti‐γ‐aminobutyric acid B receptor autoimmune encephalitis: Clinical presentation and diagnostic insights
Paramasivan, Naveen Kumar , McCombe, Jennifer A. , Fryer, James P., Datta, Abhigyan , Upadhyay, Nihar, Britton, Jeffrey W. , McKeon, Andrew , Mills, John R. , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Paramasivan, Naveen K , Stabile, Andrea , Datta, Abhigyan , Rezk, Mohamed , Britton, Jeffrey W , Flanagan, E P , McKeon, Andrew , Mills, J R , Pittock, S J , Zekeridou, Anastasia , Dubey, Divyanshu , Rezk, Mohamed, Upadhyay, Nihar, Flanagan, Eoin P. , Pittock, Sean J.

Mayo Clinic

Epilepsia | September 30, 2025 | Volume: 67 | Issue: 1 | Pages: 187-198

10.1111/epi.18654 | PMID 41026401 Get It

Abstract Objectives γ‐Aminobutyric acid B receptor (GABA B R)‐IgG (immunoglobulin G) is an intermediate‐risk paraneoplastic autoantibody often associated with seizures. We aimed to assess the clinical and oncological features of GABA B R‐IgG autoimmune encephalitis (AE) and evaluate the performance of antibody testing. Methods Patients testing positive for GABA B R‐IgG in serum/cerebrospinal fluid (CSF) at Mayo Clinic Neuroimmunology Laboratory were identified. Archived sera were retested by cell‐based assay (CBA) at 1:100 and 1:200 dilutions. A live‐cell flow cytometry–based assay (LCFBA) was developed and validated using archived sera and CSF. True positivity included patients with classic presentations of GABA B R‐IgG AE or oncological explanations for antibody presence. Results Eighty‐six patients (median age 63 years; 43 female) presented with classic presentations of GABA B R‐IgG AE: encephalopathy with prominent seizures ( n = 55), status epilepticus ( n = 23), and rapidly progressive dementia ( n = 8). In addition, 44 patients (33%) had a false‐positive result for GABA B R‐IgG characterized by non‐specific symptoms/alternate diagnoses. Malignancy was identified in 78% of true‐positive patients, predominantly small cell lung carcinoma (SCLC). Testing serum at 1:100 dilution on CBA and using tissue immunofluorescence assay (IFA) in serum and CSF improved the identification of true‐positive patients ( p < 0.001). CBA at 1:100 dilution performed better than conventional CBA (at 1:10 dilution, p < 0.001) and tissue IFA ( p = 0.031). An in‐house LCFBA showed 100% sensitivity and specificity in CSF, performing similarly to conventional CBA ( p = 0.125) in CSF, but better than tissue IFA ( p = 0.031). Furthermore, serum LCFBA performed better than conventional CBA ( p = 0.022) and tissue IFA ( p = 0.006). LCFBA had the highest diagnostic accuracy and was closely followed by CBA at 1:100 dilution. Significance GABA B R‐IgG AE often presents as encephalopathy with seizures or status epilepticus in the context of an underlying SCLC. Multimodal evaluation using tissue IFA and fixed CBA at higher dilutions improves detection of true cases. LCFBA performs very well as a diagnostic test with very high sensitivity and specificity.
The Index of Suspicion for Pulmonary Extranodal Marginal Zone Lymphoma of Mucosa Associated Lymphoid Tissue
Karanam, V., Baqir, Misbah , Kumar, Naveen

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 1, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7980-A7980

10.1164/ajrccm.2025.211.abstracts.a7980 Get It

Abstract Introduction: Pulmonary nodules are not uncommonly found in patients with Sjogren's disease. Although they frequently can be benign, nodules in the context of systemic autoimmune disease such as Sjogren's disease require broadened differentials including lymphoid intersitial pneumonia, follicular bronchiolitis, nodular lymphoid hyperplasia (NLH), amyloidosis and lung malignancy. Although lung carcinoma can occur, the most frequent malignant etiology is non-Hodgkin's lymphoma, including pulmonary extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma). On the other hand, many of these differentials are benign; however, some such as NLH can progress to lymphoma while others such as nodular amyloidosis can be associated with MALT lymphoma. As pulmonary MALT lymphoma often presents with asymptomatic nodules or consolidations, the index of suspicion by pulmonologists is crucial for diagnosis. Description: A 66 year old female nonsmoker presented with incidentally found bilateral solid and subsolid pulmonary nodules, the largest being 1.3 centimeters in the left lower lobe, in the context of calcified lymph nodes and splenic and liver calcified granulomas. As she was asymptomatic, possible differentials included chronic granulomatous disease, inflammatory/autoimmune lesions and less likely multifocal pulmonary malignancy. Fungal serologies were negative. Antinuclear antibodies, SS-A, and SS-B serologies were strongly positive. Erythrocyte sedimentation rate and rheumatoid factor were also positive. Further diagnostic workup led to a diagnosis of Sjogren's disease. Repeat 3 month CT chest showed stability of the lymphadenopathy and pulmonary nodules. However, despite stability, our pre-test probability for neoplastic pulmonary nodules had increased due to her autoimmune diagnosis. PET-CT scan was completed, showing metabolically active nodules bilaterally with a SUV range of 2-3.5, with the largest nodule having the highest uptake. Transbronchial biopsy of the largest nodule was consistent with MALT lymphoma. Discussion: The diagnosis of Sjogren's disease led to more aggressive efforts towards diagnostic certainty including a PET-CT scan and ultimately transbronchial biopsy. It is postulated that autoimmune activity in the pulmonary lymphoid tissue is what gives rise to MALT lymphoma. In one retrospective study on pulmonary nodules in patients with Sjogren's disease, greater than 70% of biopsied nodules were malignant, of which half represented MALT lymphoma. MALT lymphoma is diagnosed at the stage of disseminated disease in one third of cases, frequently recurs and has potential for aggressive transformation. Therefore, in the case of multiple pulmonary nodules in patients with Sjogren's disease, the evidence of underlying autoimmunity should increase the index of suspicion for pulmonary malignancy, including MALT lymphoma.
‘Amphiphysin-like’ IgGs Targeting Novel Synaptic Vesicle Trafficking Autoantigens (P1-8.002)
Gilligan, Michael , Mills, John R. , Vargas, Paulina, Lesnick, Connie , Basal, Eati, LaFrance‐Corey, Reghann G., Dasari, Surendra , Ζεκερίδου, Αναστασία , Pittock, Sean J, McKeon, Andrew, Vargas, Paulina, Paramasivan, Naveen Kumar , Pittock, Sean J. , Dubey, Divyanshu , McKeon, Andrew

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211028 Get It

Clinical Insights into Patients with Caspr1 and Caspr1/Contactin-1 Complex Antibodies (P4-11.024)
Swart, Grace , LaFrance‐Corey, Reghann G., Mozammel, Anousha, Mills, John R. , Paramasivan, Naveen Kumar , Klein, Christopher J. , Dubey, Divyanshu

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212283 Get It

Upper Motor Neuron-Predominant Motor Neuron Disease: A Novel Immunotherapy-Responsive Association of GAD65 Autoimmunity (P2-8.011)
Sarker, Pallab , Ζεκερίδου, Αναστασία , Klein, Christopher W., Paramasivan, Naveen Kumar , Staff, Nathan P. , Klein, Christopher, McKeon, Andrew , Pittock, Sean J. , Dubey, Divyanshu

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212221 Get It

Development of LGI1-IgG Autoimmune Encephalitis Outcome Rating Score Using the Rasch Analysis (S7.005)
Li, Xiaoyang , Ζεκερίδου, Αναστασία , López, Alfonso, Day, Gregory S. , Sánchez, Cristina Valencia, McKeon, Andrew, Pittock, Sean J, Dubey, Divyanshu , Day, Gregory S , Sadjadi, Reza , Gupta, Pranjal , Paramasivan, Naveen Kumar , Flanagan, Eoin P. , Britton, Jeffrey W. , Lopez, Alfonso, McKeon, Andrew , Pittock, Sean J. , Dubey, Divyanshu

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000208929 Get It